Skip to main navigation

Investor Relations

Overview
News & Events
Stock Information
Financial Information
Corporate Governance
Investor Resources

Press Releases

Press Releases

Year

Aug 27, 2020

Applied Molecular Transport Announces First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis

Aug 11, 2020

Applied Molecular Transport Reports Second Quarter 2020 Financial Results

Aug 05, 2020

Applied Molecular Transport Named as One of Three Finalists for the Fierce Innovations Awards for AMT-101

Jun 09, 2020

Applied Molecular Transport Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jun 04, 2020

Applied Molecular Transport Announces Pricing of Initial Public Offering

Apr 21, 2020

Applied Molecular Transport Appoints Industry Veteran Shawn Cross As Chief Financial Officer And Promotes Bittoo Kanwar, M.D. To Chief Medical Officer

Feb 18, 2020

Applied Molecular Transport Presents Preclinical Data On AMT-101, An Oral GI-Selective RhIL-10 At European Crohn’s And Colitis Organisation (ECCO)

Investor Tools

Applied | Molecular | Transport

Copyright © Applied Molecular Transport Inc. 2020. All rights reserved.